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Climate Change
politicians must heed health 
effects of climate change
The report on climate change and health 
commissioned by University College London 
and the Lancet concludes: “Climate change 
is the biggest global health threat of the 21st 
century.”1 In this report, the authors emphasise 
not only the immediacy and gravity of this threat 
but also the directness: while the poorest in 
the world will be the first affected, none will 
be spared. The escalating carbon footprint of 
the developed world has led to the present 
situation, but the rapid impact on developing 
countries such as the encroaching deserts in 
Africa is the immediate price.
This is one reason why doctors must take 
a lead in speaking out. Another is that there 
are important co-benefits of tackling climate 
change for those with long term conditions in 
the developed world, such as those that come 
from more exercise with less use of cars and 
dietary change with reduced meat consumption. 
In December this year, world governments meet 
in Copenhagen, Denmark, to negotiate a new 
UN Framework Convention on 
Climate Change. There is a real 
danger that politicians will be 
indecisive, especially in such 
turbulent economic times as 
these. Should their response be 
weak, the results for international 
health could be catastrophic. 
Doctors are still seen as respected 
and independent, largely 
trusted by their patients and the 
societies in which they practise. As leaders of 
physicians across many countries, we call on 
doctors to demand that their politicians listen 
to the clear facts that have been identified 
in relation to climate change and act now to 
implement strategies that will benefit the health 
of communities worldwide.
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NHs organisations, let’s all sign 
up to the 10:10 campaign
We have joined the 10:10 
campaign to cut our carbon 
dioxide emissions by at least 
10% during 2010.1
The business reasons for 
joining are compelling:
We must reduce our • 
dependence on oil, with its 
fluctuating and increasing 
prices, if we are to deliver 
high quality care in the medium and long term
Commitment to 10:10 is a positive investment • 
in all our futures, benefiting staff morale, 
recruitment, and retention and increasing 
patients’ engagement with their health service
Legislation and regulation such as the UK • 
government’s carbon reduction commitment 
will increasingly penalise organisations that do 
not take bold steps to cut their emissions and 
become more environmentally sustainable
Cutting energy costs is one way to increase the • 
NHS’s productivity and efficiency.
The social reasons are equally compelling:
With its responsibility to care for the health • 
of the population, the NHS should reduce its 
contribution to climate change, “the biggest 
global health threat of the 21st century”2
If we are serious about tackling health • 
inequalities we should be taking bolder action 
on climate change, which already hits the 
poorest hardest
As the largest organisation in the UK, the • 
largest employer in Europe, and one of the 
largest employers in the world, the NHS must 
demonstrate leadership at this critical time. If 
we can deliver a 10% cut in our emissions in 
2010 so can other organisations worldwide.
The 10:10 campaign takes positive, 
exemplary, and inspiring action on climate 
change (www.1010uk.org, health@1010uk.org). 
Early commitment to 10:10 can influence the 
climate change talks in Copenhagen in December 
of this year and make urgent cuts in global 
emissions a reality. We urge you to join and be 
part of the solution, so that we can all reap the 
rewards of a low carbon health service.
Deborah evans chief executive officer, NHS Bristol 
Ian Carruthers chief executive officer, NHS South West 
Janet King director, Human Resources and Facilities, Frimley 
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assisted dying debate
A baroness replies
Delamothe is right about one thing: we should 
not equate disability with terminal illness.1 Not 
all disabled people are terminally ill, though 
many terminally ill people are disabled by their 
illness. The vulnerability of disabled people to 
collateral harm from the legalisation of assisted 
dying depends on the impact of their illness, 
their degree of dependence on others, and the 
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beliefs of some that their lives are less worth 
living. Many disabled people are more vulnerable 
than most, as Delamothe seems to recognise, 
albeit somewhat grudgingly.
The strident campaign to legalise assisted 
suicide for the terminally ill is being built around 
someone who is disabled and chronically rather 
than terminally ill. Many disabled people are 
like this. Therefore it is not surprising that they 
are concerned about the underlying message: 
if you have a disabling and degenerative illness 
the way should be cleared for you to have 
assisted suicide.
One hopes that the supporters of an assisted 
dying law would see it as providing a narrowly 
defined facility to be exercised under wholly 
exceptional circumstances. Simply limiting 
it to “terminally ill adults of sound mind who 
want to die” is not nearly sufficient to meet this 
requirement.
I argued in the Lancet article that Delamothe 
cites that if assisted dying is being justified on 
grounds of personal choice and control rather 
than unrelievable suffering, it has effectively 
lost its link with terminal illness and is therefore 
more open to drift to encompass people who 
are not terminally ill. Delamothe underestimates 
the pressures that a change in the law would 
place on disabled people.
Ilora G Finlay professor of palliative medicine, Cardiff University 
and Velindre NHS Trust, Cardiff CF14 2TL finlayi@parliament.uk
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Doctors’ attitudes surveyed
Delamothe argues that it is “time for a carefully 
worded secret ballot” of UK doctors, having 
reported that 79% of the general public in a 
Harris poll believe in a “right to die” for the 
terminally ill.1
The need to clarify medical views on this 
subject was the motivation for my recently 
published survey of a large representative 
sample of UK doctors.2 I used the same 
questions as those used in surveys of the 
general public in British social attitudes 
surveys, which, like the Harris poll, have 
shown substantial public support for the 
legalisation of assisted dying.
The survey showed that the majority of UK 
doctors are opposed to the legalisation of 
euthanasia or physician assisted dying, whether 
in cases of terminal illness or not. There are some 
variations between different groups of doctors, 
the most significant being whether a doctor 
is religious. Doctors specialising in palliative 
medicine are the most opposed, with doctors 
specialising in care of the elderly being the next 
most opposed.
These findings are consistent with studies 
comparing medical and public opinion in several 
other countries.
Clive seale professor of medical sociology, Barts and the 
London School of Medicine and Dentistry, Queen Mary 
University of London, London E1 2AT c.seale@qmul.ac.uk
Competing interests: None declared.
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life is a terminal condition
Lord Carlile’s views are well known,1 2 but 
many can envisage differing thresholds and 
circumstances that are worse than death and not 
restricted to terminal illness. Since life itself is a 
terminal condition, there is a refreshing sense 
of realism in the possibility under Swiss law of 
assisted suicide in cases of unbearable suffering 
that is not the result of a terminal illness.
The attack on the World Trade Centre evidently 
led to some people committing suicide by  
leaping from the windows rather than suffer 
prolonged injury and death from the fire. 
Following these terrible circumstances, some 
people with religious convictions found comfort 
in knowing that the death of a relative had arisen 
from the unfolding alternatives rather than a 
deliberate act of suicide.3 In the current and 
different context should one be constrained 
to the alternatives for the religious reasons of 
others, or by the concerns of those who would 
not commit suicide given similar disabilities 
whether terminal or not?
Traditionally a doctor’s prime responsibility 
has been towards an individual patient, while 
not entirely neglecting wider considerations. 
Surely this should have resonance in how 
society responds, particularly when that 
patient, having reached a personal threshold, 
is seeking control over what remains of life and 
the departure from life.
The risk of exploitation is given prominence by 
those opposed to changes in the law, but these 
views seem to be detached from the everyday 
clinical reality of cases that are likely to occur. 
If approached carefully and with consultation 
with other professionals and relatives these 
cases could be dealt with sensitively and 
appropriately—and more safely.
Malcolm Bowker retired consultant psychiatrist, Cheshire 
Malcbowk@aol.com
Competing interests: MB is a subscriber to Dignity in Dying.
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Doctors, steer entirely clear
Cumberlege urges doctors to steer clear of 
assisted suicide and preserve their place in 
society as a profession with a clear purpose: to 
treat, cure, and care for sick and disabled people 
(to which I would add “and improve the health of 
the population”).1
If this is the right position for the medical 
profession, surely it also follows that since this 
position is based on professional self interest, 
society and the media should pay no attention 
whatsoever to our views on assisted suicide.
The medical profession would do well not just 
to steer clear of assisted suicide but to make it 
clear that it is not for us to influence the opinion 
of society at large.
If assisted suicide were ever to become legal 
then the position of the medical profession 
should be to have nothing to do with it. Yet that 
does not mean that society cannot press ahead 
and find another professional group to help with 
implementation.
Let us not just steer clear. Let’s steer entirely 
clear, routinely stating that this subject is very 
clearly outside our remit.
Christopher J spencer Jones director of public health,  
NHS South Birmingham, Birmingham B13 8JL  
Christopher.spencer-Jones@sky.com
Competing interests: None declared.
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end oF liFe deCisions
Authors respond to editorial
In the editorial accompanying our study, Byock 
says that we focus on practices that rarely occur at 
the end of life, such as euthanasia and physician 
assisted suicide, and pay little attention to 
more common decisions.1 2 However, detailed 
empirical reporting is necessary because of the 
intense societal, legal, and ethical debates about 
these decisions. Additionally, although some 
decisions such as life ending drug use without 
explicit patient request and palliative sedation 
are not common in palliative care overall, they are 
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Byock states that proponents of legalising 
euthanasia and physician assisted suicide and 
right to life advocates share “a deep distrust 
of doctors and the institutions in which they 
practice.”2 This claim cannot be universally 
upheld. The system that legally allows physician 
assistance in dying in the Netherlands is rightly 
based on trust in doctors, as proved by the 
regular monitoring of their actions.3 4
Agnes van der Heide associate professor, Department of Public 
Health, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, 
Netherlands a.vanderheide@erasmusmc.nl 
Judith A C rietjens postdoctoral researcher, Department of 
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Netherlands
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Counting end of life decisions
In the editorial accompanying the report from 
Van den Block and colleagues, Byock points out 
that only 22 cases of euthanasia or physician 
assisted suicide occurred (1.3% of all 1690 
non-sudden deaths).1 2 But if the 26 cases of “life 
ending without a patient request” are included 
(unfortunately translated as “involuntary 
euthanasia” in early Dutch reports of studies 
using this questionnaire3) the proportion of cases 
of assisted dying rises to 2.8%. All of these end 
of life decisions entail doctors saying yes when 
asked, “Was death caused by the use of a drug 
prescribed, supplied, or administered by you or a 
colleague with the explicit intention of hastening 
the end of life (or of enabling the patient to end 
his or her own life?)”
In the United Kingdom, use of the same 
questions with a nationally representative 
sample of doctors reporting on 2869 deaths 
(including sudden deaths) has produced figures 
of 0.21% for euthanasia, 0.00% for physician 
assisted suicide, and 0.30% for life ending 
without a patient request.4 An earlier survey 
using these questions, of 629 deaths in the UK 
in 2004, produced figures (excluding sudden 
deaths) of 0.17%, 0.00%, and 0.36%.5
Van den Block and colleagues also report the 
proportions of deaths in which actions were 
taken that entailed either an expectation or a 
partial intention that these would contribute 
to a hastened death. The wordings of the 
questions that produce these statistics are  
controversial, and reworded questions have 
produced lower estimates.4
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osteoarthritis oF the knee
precise diagnosis and treatment
The more knees wear out the more they hurt—
this is the message from a clinical epidemiology 
group in Boston.1 But that is not the whole story. 
The radiographic paper published by the same 
group last year shows that this progressive wear 
remains confined to the single compartment 
initially affected.2
By calling the condition osteoarthritis of 
the knee, the authors continue a sophistry 
that suggests that the knee is an organ like 
the pancreas, where inflammation is the key 
process, and total excision the final solution. 
However, treating unicompartmental wear by 
unicompartmental knee replacement effectively 
restores function and prevents disease 
progression over decades.3 4 Partial replacement, 
whether of the medial or lateral tibiofemoral joint 
or of the patellofemoral joint, is not only more 
functional but also much more cost effective than 
total knee replacement driven by a diagnosis of 
osteoarthritis of the knee. It could save the NHS 
over £50m a year.5
Justin Cobb professor of orthopaedics, Imperial College, Charing 
Cross Hospital, London W6 8RF 
 j.cobb@imperial.ac.uk
Competing interests: None declared.
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The classification system we used has been 
validated and used extensively in international 
research.3 4 It distinguishes specifically between 
distinct actions and intentions, as described in 
detail in the methods section.
“Principles do not depend on empirical 
data,”1 but our study provides empirical data 
on a subject that has been dominated by 
emotional unproved arguments. Although 
many people believe that euthanasia requests 
follow a lack of access to palliative care and 
that delivery of palliative care will resolve any 
euthanasia request, our data showed that 
euthanasia or physician assisted suicide was 
not disproportionately chosen by patients not 
accessing palliative care. This is an important 
message for policy makers and palliative care 
associations and should be taken into account 
when discussing the future role of palliative care.
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Doctors can be trusted
Van den Block and colleagues’ survey in Belgium 
found that high use of palliative care is associated 
with more medical decisions to hasten death.1 
This may be because the quality of palliative care 
is insufficient or because palliative care is limited 

























Lam and colleagues did not mention possible 
HIV infection in their 10-minute consultation 
on herpes zoster ophthalmicus.1 Herpes zoster 
may occur at any stage of HIV infection and be 
its first clinical presentation. In one study it was 
significantly higher among HIV positive men than 
HIV negative men (29.4 v 2.0 per 1000 person 
years),2 and the risk of developing herpes zoster 
was not associated with duration of HIV infection 
or rapid progression to AIDS.
HIV infection should always be considered in 
patients under 65 with herpes zoster. Awareness 
of herpes zoster in HIV may help to reduce the 
incidence of people presenting late with HIV 
infection (M Sethupathi et al, BASHH-ASTDA 
conference, New York, May 2008).
Kathir Yoganathan consultant physician, Singleton Hospital, 
ABM University NHS Trust, Swansea SA2 8QA  
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a/h1n1 FlU PandemiC
roche responds
The use of oseltamivir (Tamiflu) in children and 
the development of resistance from widespread 
usage have been much debated.1
Antiviral treatments are currently the only 
available therapeutic option to prevent and treat 
infection with the A/H1N1 flu virus. The product 
summary for oseltamivir shows that it is effective 
and well tolerated in children.
The European Medicines Agency approves 
oseltamivir to treat and prevent flu in those aged 
1 year and over on the basis of a positive benefit 
and risk assessment. The product summary 
shows that in otherwise healthy children (under 
12s) who had fever with either cough or coryza, 
treatment started within 48 hours of the onset 
of symptoms significantly reduces the time to 
alleviation of illness by 1.5 days compared with 
placebo. The incidence of acute otitis media was 
reduced from 26.5% in the placebo group to 16% 
in the oseltamivir group. In a group of asthmatic 
children, the median duration of illness was 
not reduced significantly in those treated with 
oseltamivir, although by day 6 of treatment 
forced expiratory volume had increased by 
10.8% in the oseltamivir group compared with 
4.7% in the placebo group.
Ongoing testing shows that the currently 
circulating pandemic virus remains susceptible 
to oseltamivir.2-4 Roche takes the issue of 
resistance seriously and is monitoring the 
situation in collaboration with established 
surveillance groups from around the world. Data 
on file at Roche show resistance to oseltamivir in 
13 isolated cases. This is in the context of testing 
for resistance in more than 2000 virus isolates 
from 119 countries and 180 clinical specimens 
from the United States.5
Michelle rashford medical director, Roche Products, Welwyn 
Garden City, Hertfordshire AL7 1TW  
michelle.rashford@roche.com
Competing interests: Roche manufactures Tamiflu.
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should flu have at least one 
respiratory symptom?
The algorithms for A/H1N1 flu currently used 
by the UK population do not seem to need any 
respiratory symptoms.1 Although information 
on various symptoms in proved A/H1N1 flu is 
lacking, the total absence of cough, coryza, or 
sore throat implies that an alternative diagnosis 
is worth considering, and the protocol should 
be modified to redirect patients to a clinician. 
We have seen proved gastrointestinal infection 
treated as A/H1N1 flu.
The automatic assumption that children with 
symptoms that could arise from any infection 
should be treated without clinical assessment 
is worrying. All children deserve a conversation 
with a clinician.
Nicholas J sharvill family doctor, Deal CT14 7EQ  
john.sharvill@nhs.net
Competing interests: None declared.
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mesothelioma Patient joUrney
researching the small things  
that matter
Two general practitioner academics who 
spent their professional lives researching 
the patient experience are facing terminal 
illness.1 2 Sweeney’s comment that “the 
more junior ranks of ancillary health 
professionals are simply unable to conceal the 
pleasure of the deployment of their authority” 
deserves to be systematically researched.
Managing serious illness requires 
collaboration between multiple professionals 
and, importantly, non-professionals.3 
Seemingly small things—an ill-chosen 
phrase, lack of eye contact, a gaping hospital 
gown, and miscommunication about the 
diagnosis—came together to erode Sweeney’s 
sense of dignity and his trust in the wider 
system of care.1
We should revisit the work of Garfinkel to 
develop a research agenda into the small things 
that matter.4 Much research on organisational 
work focuses on standard operating 
procedures. Garfinkel, in contrast, argued that 
work is irreducibly situated and contingent; 
medical work is characterised by a high degree 
of exceptionality; and the key research question 
is how, from moment to moment, staff attend 
to subtle cues from the patient, other staff, and 
the medical record, and adapt their actions and 
utterances accordingly.
My team showed that low status general 
practice staff such as receptionists have 
enormous power to shape organisational 
routines to provide interpreters for people 
with limited English.5 The difference between 
a good and disastrous patient experience was 
linked to such things as identity, mindfulness, 
and autonomy in the most junior members 
of the organisation. The agenda raised by 
our dying colleagues demands more theory 
driven research studies into how frontline 
administrative and ancillary work supports, or 
undermines, the high ideals of patient centred 
medicine.
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